{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:37:45Z","timestamp":1791873465087,"version":"4.3.4"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Taisho Pharmaceutical Co., Ltd"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Study Objectives<\/jats:title>\n                    <jats:p>A placebo (PBO)-controlled phase 3 study was conducted to evaluate the efficacy and safety of vornorexant, a novel dual orexin receptor antagonist, in Japanese patients with insomnia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Following a 2-week PBO run-in period, 596 patients with insomnia were randomized to receive 5\u00a0mg of vornorexant (VOR5), 10\u00a0mg of vornorexant (VOR10), or PBO for 2\u00a0weeks in a 1:1:1 ratio in double-blind manner, followed by a 1-week PBO run-out period. The primary and key secondary efficacy endpoints were subjective sleep latency and subjective sleep efficiency, respectively, assessed by sleep diary.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Subjective sleep latency was significantly improved at week 2 in both groups compared to PBO (differences of the least-squares mean [LSM] changes from baseline in VOR5, \u221210.6\u00a0min [95% CI = \u221214.2% to \u22127.0%] p &amp;lt; .001, and VOR10, \u221210.1\u00a0min [\u221213.8% to \u22126.5%] p &amp;lt; .001). Subjective sleep efficiency was also significantly improved at 2\u00a0weeks in both groups compared to PBO (LSM changes from baseline in VOR5, 3.41% [1.87% to 4.96%] p &amp;lt; .001, and VOR10, 2.94% [1.40% to 4.48%] p &amp;lt; .001). The most common adverse event (AE) was somnolence (VOR5: 3.1%, VOR10: 3.6%, PBO: 1.5%). No AEs of cataplexy, fall, muscular weakness, sleep paralysis, hypnagogic or hypnopompic hallucination, or excessive daytime sleepiness were reported. No withdrawal symptoms or rebound insomnia were observed in the PBO run-out period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Treatment with 5 and 10\u00a0mg of vornorexant significantly improved sleep onset latency and sleep efficiency compared with PBO without relevant safety concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>ClinicalTrials.gov ID: NCT05453136. Japan Registry of Clinical Trials ID: jRCT2031220209. A Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Phase 3 Study of TS-142 in Patients with Insomnia Disorder. https:\/\/clinicaltrials.gov\/study\/NCT05453136. https:\/\/jrct.mhlw.go.jp\/en-latest-detail\/jRCT2031220209.<\/jats:p>\n                    <jats:p>Statement of Significance Sleep disturbances lead to physical and mental health issues. Some pharmacotherapies for individuals with insomnia are available, but most of these have concerns including withdrawal, dependence, and next-day residual effects. Therefore, alternative treatment with minimal impact on these issues is highly desirable. This phase 3 study was conducted to confirm the efficacy and safety of vornorexant, a novel dual orexin antagonist having pharmacokinetic characteristics of rapid absorption and elimination, in patients with insomnia. Consequently, both tested doses showed superior efficacy compared to placebo, with significant reductions in subjective sleep latency and increases in sleep efficiency. These findings position vornorexant as a new treatment option for insomnia, offering improvements in sleep while avoiding the concerns associated with traditional hypnotics.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/sleep\/zsaf291","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T10:52:02Z","timestamp":1758883922000},"source":"Crossref","is-referenced-by-count":12,"title":["Efficacy and safety of vornorexant in Japanese patients with insomnia: a randomized, placebo-controlled phase 3 pivotal study"],"prefix":"10.1093","volume":"49","author":[{"given":"Makoto","family":"Uchiyama","sequence":"first","affiliation":[{"name":"Tokyoadachi Hospital , Tokyo ,","place":["Japan"]},{"name":"Department of Psychiatry, Nihon University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5134-3554","authenticated-orcid":false,"given":"Daiji","family":"Kambe","sequence":"additional","affiliation":[{"name":"Development Headquarters, Taisho Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Hasegawa","sequence":"additional","affiliation":[{"name":"Development Headquarters, Taisho Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Imadera","sequence":"additional","affiliation":[{"name":"Development Headquarters, Taisho Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1727-7405","authenticated-orcid":false,"given":"Hironori","family":"Yamasaki","sequence":"additional","affiliation":[{"name":"Development Headquarters, Taisho Pharmaceutical Co., Ltd. , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naohisa","family":"Uchimura","sequence":"additional","affiliation":[{"name":"Department of Neuropsychiatry, Kurume University School of Medicine , Fukuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"2026031105072042300_ref1","volume-title":"International Classification of Sleep Disorders","author":"American Academy of Sleep Medicine","year":"2014","edition":"3rd"},{"key":"2026031105072042300_ref2","doi-asserted-by":"publisher","first-page":"102121","DOI":"10.1016\/j.smrv.2025.102121","article-title":"Estimation of the global prevalence and burden of insomnia: a systematic literature review-based analysis","volume":"82","author":"Benjafield","year":"2025","journal-title":"Sleep Med Rev"},{"issue":"11","key":"2026031105072042300_ref3","doi-asserted-by":"publisher","first-page":"e2018782","DOI":"10.1001\/jamanetworkopen.2020.18782","article-title":"Incidence, persistence, and remission rates of insomnia over 5 years","volume":"3","author":"Morin","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"11","key":"2026031105072042300_ref4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.2337\/dc09-0284","article-title":"Insomnia with objective short sleep duration is associated with type 2 diabetes: a population-based study","volume":"32","author":"Vgontzas","year":"2009","journal-title":"Diabetes Care"},{"issue":"11","key":"2026031105072042300_ref5","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/hr.2013.70","article-title":"The relationship of sleep duration and insomnia to risk of hypertension incidence: a meta-analysis of prospective cohort studies","volume":"36","author":"Meng","year":"2013","journal-title":"Hypertens Res"},{"issue":"1\u20133","key":"2026031105072042300_ref6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jad.2011.01.011","article-title":"Insomnia as a predictor of depression: a meta-analytic evaluation of longitudinal epidemiological studies","volume":"135","author":"Baglioni","year":"2011","journal-title":"J Affect Disord"},{"issue":"2","key":"2026031105072042300_ref7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.5664\/jcsm.6470","article-title":"Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: an American Academy of Sleep Medicine clinical practice guideline","volume":"13","author":"Sateia","year":"2017","journal-title":"J Clin Sleep Med"},{"issue":"1","key":"2026031105072042300_ref8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s40675-023-00270-9","article-title":"Barriers in access to and delivery of behavioral sleep treatments","volume":"10","author":"Roberts","year":"2024","journal-title":"Curr Sleep Med Rep"},{"issue":"12","key":"2026031105072042300_ref9","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1056\/NEJMra1611832","article-title":"Treatment of benzodiazepine dependence","volume":"376","author":"Soyka","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026031105072042300_ref10","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/s0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"issue":"3","key":"2026031105072042300_ref11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1748-1716.2009.02068.x","article-title":"Characterization of sleep-wake patterns in a novel transgenic mouse line overexpressing human prepro-orexin\/hypocretin","volume":"198","author":"M\u00e4kel\u00e4","year":"2010","journal-title":"Acta Physiol (Oxf)"},{"issue":"7168","key":"2026031105072042300_ref12","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature06310","article-title":"Neural substrates of awakening probed with optogenetic control of hypocretin neurons","volume":"450","author":"Adamantidis","year":"2007","journal-title":"Nature."},{"issue":"19","key":"2026031105072042300_ref13","doi-asserted-by":"publisher","first-page":"10911","DOI":"10.1073\/pnas.96.19.10911","article-title":"Orexin A activates locus coeruleus cell firing and increases arousal in the rat","volume":"96","author":"Hagan","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1-2","key":"2026031105072042300_ref14","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.brainres.2005.04.064","article-title":"Selective stimulation of orexin receptor type 2 promotes wakefulness in freely behaving rats","volume":"1048","author":"Akanmu","year":"2005","journal-title":"Brain Res"},{"issue":"4","key":"2026031105072042300_ref15","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0092-8674(00)81973-x","article-title":"Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"issue":"29","key":"2026031105072042300_ref16","doi-asserted-by":"publisher","first-page":"10529","DOI":"10.1523\/JNEUROSCI.0784-11.2011","article-title":"Acute optogenetic silencing of orexin\/hypocretin neurons induces slow-wave sleep in mice","volume":"31","author":"Tsunematsu","year":"2011","journal-title":"J Neurosci"},{"issue":"2","key":"2026031105072042300_ref17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"issue":"2","key":"2026031105072042300_ref18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.biopsych.2014.10.003","article-title":"Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials","volume":"79","author":"Herring","year":"2016","journal-title":"Biol Psychiatry"},{"issue":"3","key":"2026031105072042300_ref19","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/s0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"issue":"9197","key":"2026031105072042300_ref20","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"key":"2026031105072042300_ref21","volume-title":"BELSOMRA (suvorexant) [package insert]","year":"2021"},{"key":"2026031105072042300_ref22","volume-title":"DAYVIGO (lemborexant) [package insert]","year":"2023"},{"key":"2026031105072042300_ref23","volume-title":"QUVIVIQ (daridorexant) [package insert]","year":"2022"},{"issue":"13","key":"2026031105072042300_ref24","doi-asserted-by":"publisher","first-page":"115489","DOI":"10.1016\/j.bmc.2020.115489","article-title":"Discovery of ORN0829, a potent dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"28","author":"Futamura","year":"2020","journal-title":"Bioorg Med Chem"},{"issue":"5","key":"2026031105072042300_ref25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1111\/bcpt.13930","article-title":"Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant\/TS-142 in healthy Japanese participants following single\/multiple dosing: randomized, double-blind, placebo-controlled phase-1 studies","volume":"133","author":"Kambe","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"2026031105072042300_ref26","doi-asserted-by":"publisher","first-page":"e1183","DOI":"10.1002\/prp2.1183","article-title":"Preclinical metabolism and the disposition of vornorexant\/TS-142, a novel dual orexin 1\/2 receptor antagonist for the treatment of insomnia","volume":"12","author":"Konno","year":"2024","journal-title":"Pharmacol Res Perspect"},{"issue":"7","key":"2026031105072042300_ref27","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00213-022-06089-6","article-title":"Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study","volume":"239","author":"Uchiyama","year":"2022","journal-title":"Psychopharmacology (Berl)"},{"key":"2026031105072042300_ref28","volume-title":"PFSB\/ELD Notification No. 1213-1: Guidelines on the Clinical Evaluation of Sleeping Drugs","author":"Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare","year":"2011"},{"key":"2026031105072042300_ref29","doi-asserted-by":"publisher","first-page":"e081124","DOI":"10.1136\/bmj-2024-081124","article-title":"CONSORT 2025 statement updated guideline for reporting randomized trials","volume":"389","author":"Hopewell","year":"2025","journal-title":"BMJ"},{"issue":"4","key":"2026031105072042300_ref30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.31662\/jmaj.2020-0002","article-title":"The STOP-Bang test is useful for predicting the severity of obstructive sleep apnea","volume":"3","author":"Oshita","year":"2020","journal-title":"JMA J"},{"issue":"4","key":"2026031105072042300_ref31","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the insomnia severity index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med"},{"issue":"10","key":"2026031105072042300_ref32","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1185\/03007990903167415","article-title":"Interpreting score differences in the insomnia severity index: using health-related outcomes to define the minimally important difference","volume":"25","author":"Yang","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"11","key":"2026031105072042300_ref33","first-page":"1836","article-title":"1,4-benzodiazepine, temazepam (K 3917), its effect on some psychological parameters of sleep and behaviour","volume":"25","author":"Hindmarch","year":"1975","journal-title":"Arzneimittelforschung."},{"issue":"7","key":"2026031105072042300_ref34","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"issue":"Suppl 3","key":"2026031105072042300_ref35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","article-title":"The measurement of disability","volume":"11","author":"Sheehan","year":"1996","journal-title":"Int Clin Psychopharmacol"},{"issue":"1\u20132","key":"2026031105072042300_ref36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3109\/00207459008994241","article-title":"Subjective and objective sleepiness in the active individual","volume":"52","author":"Akerstedt","year":"1990","journal-title":"Int J Neurosci"},{"key":"2026031105072042300_ref37","doi-asserted-by":"publisher","DOI":"10.1037\/10020-000","volume-title":"The Measurement and Appraisal of Adult Intelligence","author":"Weschsler","year":"1939","edition":"1st ed."},{"issue":"1","key":"2026031105072042300_ref38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/0165-0327(90)90009-W","article-title":"The benzodiazepine withdrawal symptom questionnaire","volume":"19","author":"Tyrer","year":"1990","journal-title":"J Affect Disrord"},{"issue":"12","key":"2026031105072042300_ref39","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry"},{"key":"2026031105072042300_ref40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.sleep.2016.05.013","article-title":"Nationwide epidemiological study of insomnia in Japan","volume":"25","author":"Itani","year":"2016","journal-title":"Sleep Med"},{"issue":"8","key":"2026031105072042300_ref41","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1523\/JNEUROSCI.19-08-03171.1999","article-title":"Hypothalamic hypocretin (orexin): robust innervation of the spinal cord","volume":"19","author":"van den Pol","year":"1999","journal-title":"J Neurosci"},{"issue":"12","key":"2026031105072042300_ref42","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1016\/j.peptides.2009.07.025","article-title":"Involvement of orexin-A on micturition reflex in normal and cyclophosphamide-induced cystitis bladder in rat","volume":"30","author":"Kobayashi","year":"2009","journal-title":"Peptides"},{"issue":"35","key":"2026031105072042300_ref43","doi-asserted-by":"publisher","first-page":"e2207531119","DOI":"10.1073\/pnas.2207531119","article-title":"Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients","volume":"119","author":"Evans","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2026031105072042300_ref44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa2301940","article-title":"Oral orexin receptor 2 agonist in narcolepsy type 1","volume":"389","author":"Dauvilliers","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"2026031105072042300_ref45","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1037\/a0034401","article-title":"Nocturia reported in nightly sleep diaries: common occurrence with significant implications?","volume":"33","author":"Bliwise","year":"2014","journal-title":"Health Psychol"},{"issue":"10","key":"2026031105072042300_ref46","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1007\/s11136-013-0404-y","article-title":"The health-related quality-of-life impact of nocturnal awakenings in the middle-aged and older Finnish population","volume":"22","author":"V\u00e4\u00e4t\u00e4inen","year":"2013","journal-title":"Qual Life Res"},{"key":"2026031105072042300_ref47","volume-title":"U.S. Food and Drug Administration Assessment of Abuse Potential of Drugs: Guidance for Industry","year":"2017"},{"issue":"07","key":"2026031105072042300_ref48","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.5664\/jcsm.7228","article-title":"Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment","volume":"14","author":"Smith","year":"2018","journal-title":"J Clin Sleep Med"}],"container-title":["SLEEPJ"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsaf291\/64408082\/zsaf291.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/3\/zsaf291\/64408082\/zsaf291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/sleep\/article-pdf\/49\/3\/zsaf291\/64408082\/zsaf291.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T09:07:30Z","timestamp":1773220050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsaf291\/8265965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,9,26]]},"published-print":{"date-parts":[[2026,3,11]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsaf291","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,26]]},"article-number":"zsaf291"}}